Bulls ban Portis eight games for breaking teammate's jaw
Keuchel looks to continue success against Yankees in ALCS
Defence responds to cyber attack incident
Oppn demands probe into junior Shah's business
Four of a family, guard found murdered in northeast Delhi
FDA Approves First "Living Drug" To Treat Childhood Leukemia
31 August 2017, 01:45 | Franklin Nunez
First gene therapy coming to US after FDA approval
Some 83 percent of those given the therapy were in remission within three months of treatment, the agency said.
The therapy was evaluated in clinical testing involving 63 children and young adults with relapsed or refractory B-cell ALL.
Kymriah is a type of personalized immunotherapy known as CAR-T, or chimeric antigen receptor T-cell therapy. "Not only does Kymriah provide these patients with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials".
In response to the possibility of CRS development, the FDA has also expanded the approval of tocilizumab (Actemra; Genentech) to treat CAR-T cell-induced severe or life-threatening CRS in patients 2 years of age and older.
"We've never seen anything like this before and I believe this therapy may become the new standard of care for this patient population", Dr Stephan Grupp of Children's Hospital of Philadelphia said in a statement. Kymriah is intended for people with B-cell ALL whose cancer hasn't responded to or has returned after treatment, the FDA said.
It's too soon to tell how widely applicable CAR-T will be - it's especially suited to leukemia since infusing patients with T-cells is relatively simple. However, there were some severe side effects observed in study.
"Through our collaboration with Novartis, we are creating the next wave of immunocellular cancer treatments, and are eager to progress CAR-T therapy in a host of hematologic and other cancer types", said Carl June, MD, Professor of Immunotherapy, Director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine.
Kymriah treatment also has the possibility of serious side effects, including cytokine release syndrome (CRS), which consists of high fever and flu-like symptoms and can be life-threatening, and neurological events, which are also life-threatening.
A spokeswoman for Switzerland-based Novartis declined to say how much the drug will cost, though analysts have estimated a price of $500,000 or more. Research is therefore focusing for now on refining the therapy for patients of this disease. It is the first gene therapy of its kind to hit the USA market. The agency said that 69% of patients developing the condition during vehicle T-cell trials "had complete resolution of CRS within 2 weeks following one or two doses" of tocilizumab, which inhibits interleukin-6. More than half were children and teens.
Fitbit Ionic fitness smartwatch
They are the Fitbit Ionic - a new smartwatch , the Fitbit Flyer wireless headphones and the Fitbit Aria 2 - a smart scale. Fitbit Flyer is a headset that's meant to pair with the Ionic smart watch, but could be used with any Bluetooth device.
This Week at NASA: The Epic Solar Eclipse and More
Although Monday's eclipse was peaking over two minutes in the path of totality, the 2024 eclipse will have peaks of 4½ minutes. Eclipse-viewing glasses that provided a safe way to look at the sun during the eclipse were in short supply nationwide.
Four Cups Coffee a Day Could Lower Death Risk
Adela Navarro, a cardiologist at Hospital de Navarra in Spain, was presented at the ESC's conference on August 27. A new study says having an extra cup isn't just a good idea, but may be healthy for you too.
'The Texas Chain Saw Massacre' Director Tobe Hooper Dies At 74
They end up encountering a family of cannibals, including the human skin-masked, chain saw-wielding Leatherface (Gunnar Hansen). Numerous spinoffs have also been produced, most recently a prequel titled " Leatherface " to be released in September.